The United States Food and Drug Administration (FDA) granted this Thursday the final approval as the first treatment against COVID-19 to antiviral Remdesivir, of Gilead, to date the only one with authorization from the regulator to treat the disease.
In May, the Gilead Sciences antiviral received emergency authorization, a formula to allow use during the pandemic of the treatment still in its experimental stage, and now the FDA granted final approval for cases of COVID-19 patients hospitalized.
Remdesivir has allowed shorter recovery periods in some severe cases of COVID-19, although the World Health Organization (WHO) recently considered, after analyzing provisional data, that the antiviral, as well as others that have been administered to COVID-19 patients, has a almost negligible impact in reducing mortality.
The leading American epidemiologist, Dr. Anthony Fauci, has championed the use of Remdesivir, which is being administered to patients in the United States and with whom the president was treated of the United States, Donald Trump, during his convalescence earlier this month.
More than two million doses
With the authorization received this Thursday, Remdesivir becomes the only treatment authorized in the US for COVID-19, which has infected more than 41 million people worldwide, although there are other treatments that already have emergency authorization like the use of plasma.
“It is incredible that in less than a year since the first reports of infected by the disease known as COVID-19 in the United States we have a treatment that is available to all patients they need it, “Gilead CEO Daniel O’Day said in a statement.
The pharmaceutical company expects to manufacture more than two million doses of the treatment this year, which is administered by intravenously, and multiply that production capacity during the year 2021.
To do this, the company, which specializes in cancer or HIV treatments, has a network of suppliers and manufacturers around the world.